ArticleHistopathology2025
Diagnostic accuracy and clinical outcomes of patients diagnosed with clear cell papillary renal cell tumour at renal mass biopsy.
Article in Histopathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic value of percutaneous sampling in Bosniak III-IV renal cysts: a systematic review and meta-analysis.The Canadian journal of urology · 2026Pooled it
- Clinicopathological features and prognostic factors of clear cell papillary renal cell tumor: a retrospective population-based analysis.Translational andrology and urology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClear cell papillary renal cell tumour (CCPRCT) is a clinically indolent neoplasm. The diagnosis of CCPRCT at renal mass biopsy (RMB) may facilitate conservative management; however, this can be challenging in small samples and there are limited data on the outcome of patients managed conservatively. This study aimed to: (1) evaluate concordance between RMB and nephrectomy for the diagnosis of CCPRCT, and (2) determine the clinical outcomes of patients with CCPRCT, particularly those who have undergone conservative management. METHODS AND
resultsWe reviewed all cases at our institution where CCPRCT was diagnosed or included in the differential diagnosis at RMB. In all, 65 RMB with a diagnosis/differential diagnosis of CCPRCT were identified, including 25 patients who had subsequent surgical resection. Of cases where CCPRCT was the likely or favoured diagnosis on RMB (n = 19), the final diagnosis was concordant in 16/19 (84%). Discordant cases comprised clear cell renal cell carcinoma (ccRCC) (n = 1) and RCC with fibromyomatous stroma (n = 2). In all, 15 patients were managed with active surveillance (median follow-up 34 months) and 26 were treated with ablation (median follow-up 37 months). There was no recurrence, metastasis, or death in the cohort.
conclusionCCPRCT can be reliably diagnosed at RMB in most cases if strict morphologic and immunohistochemical (IHC) criteria are applied. Furthermore, there was no adverse behaviour among patients managed nonsurgically in our cohort. It is important, however, to recognize the limitations of RMB, particularly given that occasional examples of ccRCC can show foci resembling CCPRCT. Pathologists and treating clinicians should be aware of the limitations of RMB when considering conservative management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.